Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glu-REST Study
2024-510968-22-00Phase 2Suspended
- Sponsor
- Ente Ospedaliero Cantonale
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in restless legs syndrome (RLS) comparing REL-1017 with Placebo (2 arms). Primary endpoint: Percentage of responders to REL-1017 treatment. Started Feb 2024; status: suspended.
02
Drugs
esmethadone
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2024-510968-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510968-22-00.